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Abstract: Bitter substances are contained in many plants, are often toxic and can be present in spoiled
food. Thus, the capacity to detect bitter taste has classically been viewed to have evolved primarily
to signal the presence of toxins and thereby avoid their consumption. The recognition, based on
preclinical studies (i.e., studies in cell cultures or experimental animals), that bitter substances
may have potent effects to stimulate the secretion of gastrointestinal (GI) hormones and modulate
gut motility, via activation of bitter taste receptors located in the GI tract, reduce food intake and
lower postprandial blood glucose, has sparked considerable interest in their potential use in the
management or prevention of obesity and/or type 2 diabetes. However, it remains to be established
whether findings from preclinical studies can be translated to health outcomes, including weight
loss and improved long-term glycaemic control. This review examines information relating to the
effects of bitter substances on the secretion of key gut hormones, gastric motility, food intake and
blood glucose in preclinical studies, as well as the evidence from clinical studies, as to whether
findings from animal studies translate to humans. Finally, the evidence that bitter substances have
the capacity to reduce body weight and/or improve glycaemic control in obesity and/or type 2
diabetes, and potentially represent a novel strategy for the management, or prevention, of obesity
and type 2 diabetes, is explored.
Keywords: bitter substances; gut hormones; gastric emptying; gastric motor function; food intake;
postprandial blood glucose; preclinical studies; human studies; obesity; type 2 diabetes
1. Introduction
There has been increasing interest in the capacity of bitter substances to regulate
energy intake and improve glycaemic control, based on reports from preclinical models
(i.e., studies in cell cultures or animals) [1–3] that bitter substances have potent effects to
secrete gastrointestinal (GI) hormones and slow gastric emptying. It is now well established
that these gut functions play important roles in the regulation of both acute energy intake
and postprandial glycaemia [4–7]. Thus, bitter substances may potentially represent a novel
approach to the management or prevention of obesity and its comorbidities, particularly
type 2 diabetes. This is an important issue, given that the efficacy of the majority of
currently available treatments for obesity is limited. While lifestyle changes (reduction in
energy intake, increased physical activity) lead to weight loss, which, even when modest, is
associated with meaningful reductions in the risk of type 2 diabetes, long-term adherence
to such interventions is usually poor [8]. The critical importance of the gut is attested to by
the efficacy of bariatric surgery in producing sustained weight loss in the morbidly obese
and marked improvement in glycaemic control in patients with type 2 diabetes, the latter
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even before major weight loss occurs [5]. Pharmacological options for the management
of obesity are limited. Their use is often associated with adverse effects, particularly
nausea, and their effects on body weight are usually limited, possibly because longer-term
effective suppression of energy intake is dependent on the interaction of a number of
mechanisms. The use of agonists of glucagon-like peptide-1 (GLP-1) in the management
of type 2 diabetes and, more recently in higher dosage, obesity is now widespread [9–12].
Weight loss may be greater with higher-dose GLP-1 agonists, but as with all anti-obesity
medication, the cost is substantial, particularly as sustained use may be required to prevent
weight regain. Thus, there remains an urgent need to identify novel and inexpensive
strategies that stimulate these gut functions without adverse effects, to promote the longer-
term suppression of energy intake, clinically meaningful weight loss and, in type 2 diabetes,
improved glycaemic control.
In studies on both cell lines and experimental animals bitter agonists have been
shown to potently stimulate cholecystokinin (CCK), GLP-1 and ghrelin [3,13]. Furthermore,
bitter tastants modulate contractility in mouse gastric muscle strips and slow gastric
emptying [14,15]. These findings in preclinical studies have triggered considerable interest
in the investigation of the effects of bitter agonists in clinical studies, to determine whether
their effects can be reproduced in humans and, if so, if they are associated with reductions
in energy intake and/or postprandial glycaemic excursions. As will be discussed, while
some clinical studies have reported effects of bitter substances to stimulate GLP-1 and
CCK [16,17], suppress ghrelin [14,18], modulate gastric motility [19] and/or suppress
energy intake [16,18,19], the observed effects are inconsistent and often modest. Moreover,
only two studies have, to date, reported effects to lower postprandial blood glucose in
humans [17,20].
This review provides a brief summary of key aspects of the GI sensing of bitter
substances by luminal bitter receptors. The focus is the evaluation of information relating
to the effects of bitter substances on the secretion of gut hormones, gastric emptying and
GI motility, energy intake and blood glucose in preclinical and clinical studies. Finally,
we explore the question as to whether there is evidence to support the concept that bitter
substances have the capacity to reduce body weight and/or improve glycaemic control in
obesity and/or type 2 diabetes, with the inherent potential for their use in the prevention
and/or management of these disorders.
2. Sensing of Bitter Substances in the GI Lumen
In contrast to sweet, umami or ‘fat’ tastes (which indicate nutrient availability), bitter
taste is inherently aversive and has been viewed traditionally as having evolved primarily
to warn against the presence of toxins, particularly in plants, or signal spoiled food [21].
Many foods and other substances taste bitter and are, therefore, unpleasant to ingest.
However, bitter receptors, like receptors for nutrients [22,23], are present not only in
the oral cavity [24], but throughout the GI tract on enteroendocrine cells [23,25,26]. The
recognition that their GI sensing may trigger beneficial metabolic effects, has, in recent
years, fuelled substantial interest in a better understanding of GI bitter sensing and the
investigation of the GI effects of bitter tastants. Unlike dietary macronutrients, bitter
substances are devoid of energy and, accordingly, do not contribute to overall caloric
intake, which represents an inherent advantage.
2.1. Sources of Bitter Compounds
Natural bitter-tasting compounds are contained in many foods that provide nutrition
and contribute to health, including extracts of many plants (e.g., Hoodia gordonii, Gentiana
scabra, Humulus lupulus L. flower, bark of the cinchona tree) as well as plant-based foods
(e.g., Brassica vegetables and certain fruit), and processed dairy products, and include
phenols, flavonoids and glucosinolates, amongst many others. They can also be found in
animal-derived foods or generated during the process of food aging or spoilage [27,28].
Furthermore, Maillard and fermentation reactions can generate bitter compounds. Many
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chemically synthesised compounds, including denatonium benzoate, phenylthiocarbamide
or 6-n-propylthiouracil (the latter two are often used to determine bitter taste sensitivity
experimentally), as well as many drugs, have a strong bitter taste [29–33]. Bitter compounds
are not only numerous (the number has been estimated to be in the tens of thousands [34]),
but are also each characterised by a unique and diverse structure, consisting of phenols,
esters, fatty acids, hydroxy fatty acids, amines, flavonoids, amongst many others, indicative
of a broad range of bitter chemotypes [31,34].
2.2. Bitter Taste Receptors
Bitter tastants are detected by taste 2 receptors (TAS2Rs), which are members of
the GPCR superfamily of receptors [34,35]. A large number of receptor subtypes has
been identified in various species, including current totals of 25 in humans and >30 in
rodents [36]. While some bitter compounds activate a single TAS2R subtype, the majority
activates a range of TAS2R subtypes, although the combination of subtypes varies [34]. For
example, salicin, from willow bark, activates TAS2R16, and both phenylthiocarbamide and
propylthiouracil interact only with TAS2R38 [34]. In contrast, quinine, an extract from the
bark of the cinchona tree, activates nine (TAS2R4, 7, 10, 14, 39, 40, 43, 44, 46) and denatonium
benzoate eight (TAS2R4, 8, 10, 13, 39, 43, 46, 47) subtypes, of which five are in common with
quinine. Quassin, an extract of the tropical quassia tree, activates five subtypes (TAS2R4, 10,
14, 46, 47) [34], of which four are in common with both quinine and denatonium benzoate.
Bitter substances that activate differing combinations of receptor subtypes include sodium
cyclamate, which activates TAS2R1 and 38, and sinigrin, found in cruciferous plants, which
activates TAS2R16 and 38 [34]. That bitter substances activate different combinations of
receptor subtypes (with varying overlap between individual compounds) may account
for why only a limited number of TAS2Rs have the capacity to detect so many bitter
compounds. In the absence of a comprehensive understanding of either the function(s) of
each receptor subtype or the location and distribution of receptor subtypes on specific cells
(e.g., enteroendocrine cells), the variability in receptor activation across bitter substances
represents a major challenge to the clarification of their physiological roles and therapeutic
potential.
Single nucleotide polymorphisms have also been described in TAS2Rs and shown
to be associated with individual differences in bitter taste perception, food preferences
and/or food consumption [32,33,37,38]. Thus, while bitter taste perception is reproducible
in a given individual, the effects of bitter substances also vary between individuals. A
well-documented example of a polymorphism is the ability to taste phenylthiocarbamide
and 6-n-propylthiouracil, which is genetically determined by the TAS2R38 gene [39].
Based on the molecular structure of this receptor, individuals can be categorised into two
common phenotypes, i.e., those that can taste these compounds and those that are ‘non-
tasters’ [38,39]. The effect(s) of gene polymorphisms on the sensitivity to bitter compounds
in extra-oral locations, including the GI tract, and how genetic variations may modify these
effects remain to be clarified.
In contrast to knowledge relating to the characteristics of nutrient receptors, including
their localisation and distribution along the GI tract, which has been reviewed in detail
elsewhere [22,40–48], information regarding the regional distribution of TAS2Rs, and
the functions of specific subtypes, is limited. Evaluation of the putative TAS2Rs 1 to
12 gene transcripts (except 11, which is not a functional gene) from rat antral, fundic
and duodenal mucosa demonstrated a greater number of bitter receptor subtypes in the
duodenum than the stomach [25]. In another study, which investigated locations of TAS2Rs
by RNA sequencing on intestinal cells of rhesus macaques, only TAS2R1, 3, 4, 5, 19, 20,
38 and 46 were expressed in the duodenum, ileum and colon, with greater expression of
TAS2R38 in the small, than the large, intestine [49]. Based on these observations, targeted
administration of bitter compounds directly into the small intestine may potentially be
associated with greater potency. However, an important caveat is that animal receptor
subtypes may not correspond to those in humans. Knowledge relating to the functions of
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individual receptor subtypes is limited, but recent studies have defined roles for specific
receptor subtypes in the regulation of gut hormones. For example, TAS2R5 and 38 may be
involved in the release of GLP-1 from human L-cells and HuTu-80 cells, respectively [50,51],
and TAS2R5 and 6 in ghrelin secretion [52]. An improved understanding of the distribution
of TAS2Rs along the GI tract in humans, and the specific functions of individual receptor
subtypes, will be critical to effective targeting of the administration of bitter substances to
optimise bitter agonist-gut interactions.
3. Effects of Bitter Substances on Gut Hormone Release
A large number of gut hormones have been identified and many, including CCK,
PYY, GLP-1, glucose-dependent insulinotropic polypeptide (GIP), ghrelin, motilin, oxynto-
modulin, are pivotal to the regulation of gut motor function, energy intake and/or blood
glucose [53–58]. CCK, PYY, GLP-1 and ghrelin are probably the best characterised. CCK,
PYY and GLP-1 all have potent effects to modulate gastropyloroduodenal motility and
slow gastric emptying, and reduce energy intake [5]. The critical involvement of endoge-
nous hormones in these effects was confirmed by studies, in which administration of
specific hormone receptor antagonists was shown to attenuate the suppression of energy
intake [59–61]. These hormones also have potent effects to reduce energy intake when
administered intravenously [62–64]. In contrast to CCK, PYY and GLP-1, ghrelin, whose
circulating concentrations are high in the fasting state and thought to play a role in the
initiation of eating, is suppressed by nutrients [57]. Once released, gut hormones exert
their effects in part by activating specific receptors on vagal afferents [65,66], but may also
have direct effects in brain centres involved in appetite regulation [5]. GLP-1, which is one
of the two ‘incretin’ hormones (the other being GIP), is a physiological modulator of post-
prandial glycaemia, stimulating insulin and suppressing glucagon in a glucose-dependent
manner [67], and slowing gastric emptying [11,53,68,69]. GLP-1 agonists and dipeptidyl
peptidase-4 (DPP-4) inhibitors, which prevent degradation of endogenously secreted active
GLP-1, are now used extensively in the management of type 2 diabetes to improve blood
glucose control [10,12].
The presence of bitter substances in the GI lumen, following oral consumption or direct
luminal administration, initiates a cascade of intracellular events culminating in the release
of a number of gut hormones [3,70,71]. A substantial number of studies have evaluated
the effects of bitter substances on gut hormone secretion in preclinical studies (Table 1). A
range of bitter substances appear to have potent stimulatory effects, particularly on CCK
and GLP-1, as well as ghrelin, in the models used. In contrast, effects on PYY are poorly
defined. Only a small number of studies has been performed in humans [16–20,72–76]
(Table 2). These studies have yielded inconsistent outcomes and, perhaps surprisingly in
view of the preclinical outcomes, if positive, the observed effects have been modest. The
following sections will review evidence on the effects of bitter substances on the secretion
of CCK, GLP-1, PYY and ghrelin, based on studies in both preclinical models and humans.
3.1. Cholecystokinin
3.1.1. Outcomes of Preclinical Studies
The effects of bitter substances on CCK secretion have only been investigated in
animal or human cell lines, and gut tissues ex vivo [2,13,77–79]. In mouse STC-1 or Caco-2
cells, matured hop bitter acids (MHBA, an oxidised bitter extract from the hops flower,
Humulus lupulus L.), denatonium benzoate and phenylthiocarbamide all stimulated CCK
release dose-dependently, MHBA 20- to 80-fold and denatonium benzoate 100- to 300-
fold, while phenylthiocarbamide only resulted in a 1.5-fold increase [2,77,78]. In both
excised rat intestinal tissue and the human enteroendocrine cell line, HuTu-80, steroid
glycosides (extracted from the succulent plant, Hoodia gordonii), an agonist for hTAS2R7
and 14, stimulated CCK 1.5- to 3-fold, respectively, effects abolished by administration
of the TAS2R14 antagonist, compound 03A3 [13]. Moreover, 1,10-phenanthroline, which
Nutrients 2021, 13, 1317 5 of 21
selectively activates TAS2R5, stimulated CCK, from rat duodenal segments; in contrast, the
TAS2R14-specific agonist, flufenamic acid, apparently decreased CCK release [74].
Table 1. Effects of bitter substances on gut hormone secretion in preclinical models.
Bitter Tastant Model Doses Given/Location ofDelivery
Approx. Equivalent Dose
in a 70-kg Human 1
Observed Effect Ref #
Berberine STC-1 cells 1, 10, 100, 200 µM - ↑ GLP-1 [80]
NCI-H716 cells 1, 10, 100, 200 µM - ↑ GLP-1 [81]
Chloroquine Human fundic cells 0.3–10 mM - ↑ Ghrelin [52]
Denatonium benzoate STC-1 cells 1–10 mM - ↑ CCK [2]
NCI-H716 cells 2, 10 mM - ↑ GLP-1, PYY [3]
Human fundic mucosa 0.5, 1, 5 mM - ↑ Ghrelin [52]
Mice 1 mg/kg/oral ≈70 mg ↑ GLP-1 [3]
Mice 60 µmol/kg/IG ≈1.8 g ↑ GLP-1 [1]
Epicatechin gallate MGN3-1 cells 10 µM - ↓ Ghrelin [82]
500 µM - ↑ Ghrelin
Erythromycin A Human fundic mucosa 0.03, 0.3, 1 mmol/L - ↑ Ghrelin [52]
Flufenamic acid Rat ex-vivo segments: [79]
- duodenal 10 µM - ↓ CCK
- ileal 10 µM - ↑ GLP-1↔ PYY
Gallic acid MGN3-1 cells 10 µM - ↓ Ghrelin [82]
Gentiana scabra extract NCI-H716 cells 100–750 µg/mL - ↑ GLP-1 [83]
Hoodia gordonii HuTu-80 cells 10 mM - ↑ CCK [13]
KDT501 STC-1 cells 10 µM - ↑ GLP-1 [84]
Mice 150 mg/kg/oral ≈10 g ↑ GLP-1 [84]
Mature hop bitter acids STC-1 cells 50, 100, 200 µg/mL - ↑ CCK, GLP-1
↔ PYY
[78]
Ofloxacin NCI-H716 cells 10, 50, 100 mM - ↑ GLP-1 [85]
1,10-Phenanthroline NCI-H716 cells 10–500 µM - ↑ GLP-1 [51]
Human fundic mucosa 0.1, 1 mM - ↑ Ghrelin [52]
Rat ex-vivo segments:
[79]- duodenal 150 µM - ↑ CCK
- ileal 150 µM - ↑ GLP-1↔ PYY
Phenylthiocarbamide STC-1 cells 2, 5, 10 mM - ↑ CCK [2]
Caco-2 cells 10 mM - ↑ CCK [77]
Human fundic cells 0.3–10 mM - ↑ Ghrelin [52]
Propylthiouracil Human fundic cells 0.3–10 mM - ↑ Ghrelin [52]
Mice 200 mg/kg/IG ≈14 g ↑ GLP-1 [50]
Qing-Hua granules Mice 3.75, 7.5, 15 g/kg/d/IG ≈263–1050 g ↑ GLP-1 [86]
Quinine hydrochloride NCI-H716 cells 0.5, 1, 2 mM - ↑ GLP-1 [3]
Mice 160 µmol/kg/IG ≈4 g ↔ GLP-1, ghrelin [1]
Vanillic acid Rat ileal segments 151.17 µM - ↑ GLP-1 [79]
Wild bitter gourd STC-1 cells 100, 500, 1000 µg/mL - ↑ GLP-1 [87]
Mice 5 g/kg/IG ≈350 g ↑ GLP-1 [87]
CCK, cholecystokinin; GLP-1, glucagon-like peptide-1; IG, intragastric; PYY, peptide YY. 1 Only calculated for whole-animal studies, 2 bitter
compound derived from isohumulone, an extract from the hops plant.
3.1.2. Outcomes of Studies in Healthy Humans
In healthy males, administration of amarasateTM (a supercritical CO2 extract from New
Zealand native hops), in a dose of 500 mg, given either in an acid-resistant capsule (to target
small intestinal bitter receptors) or a standard capsule (to release its content in the stomach)
was reported to stimulate CCK in response to a subsequent lunch, consumed 60 min and
30 min after intestinal- and gastric-targetted administration, respectively, as well as a snack,
consumed 120 min after lunch [72], although the magnitude of the effect was not reported.
In contrast, in healthy males and females, 18 mg quinine hydrochloride, ingested orally in
an acid-resistant capsule did not increase absolute plasma CCK concentrations, although
the change in plasma CCK relative to baseline was slightly greater 30 min after consumption
of an ad-libitum standardised buffet meal (~0.9 ± 0.6 vs. 0.5 ± 0.8 ng/mL) [16]. Moreover,
60-min intraduodenal infusions of quinine hydrochloride, providing 75 mg [74], or 37.5 mg,
75 mg and 225 mg [76], had no effect on plasma CCK in healthy, lean men. In these
latter studies the relatively low infusion rate may have been insufficient to reach a critical
threshold for activation of TAS2Rs [20].
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Table 2. Effects of bitter substances on gut hormone secretion in healthy humans.
Bitter tastant Model Doses Given/Location of Delivery Observed Effect Ref #
AmarasateTM 1 Males 500 mg in acid-resistant or standard
capsules/oral
↑ CCK, GLP-1, PYY [72]
Denatonium benzoate Females 1 µmol/kg bolus/IG [≈32 mg] 2 ↔ Ghrelin [19]
Quinine hydrochloride Males 10 µmol/kg bolus/IG [≈270 mg] ↓ Ghrelin [18]
Males and females 18 mg in acid-resistant capsule/oral ↑ CCK [16]
Males and females 75 mg/ID over 60 min ↔ CCK, GLP-1, PYY [74]
Females 10 µmol/kg bolus/IG [≈270 mg] ↓ Ghrelin [75]
Males 37.5, 75, 225 mg/ID over 60 min ↔ CCK [76]
Males 275, 600 mg bolus/IG 30 min before meal ↑ GLP-1 [17]
Males 600 mg bolus/IG 60 min before meal, ID 30 min
before meal
↑ GLP-1 [20]
Secoiridoids 3 Males and females 100 mg/oral (microencapsulated) incorporated
in custard
↑ GLP-1↔ PYY, ghrelin [73]
CCK, cholecystokinin; GLP-1, glucagon-like peptide-1; ID, intraduodenal; IG, intragastric; PYY, peptide YY. 1 Supercritical CO2 extract
from New Zealand native hops, 2 approximately equivalent dose in a 70-kg human, 3 bitter compound derived from Gentiana lutea plant.
3.2. Glucagon-Like Peptide-1
3.2.1. Outcomes of Preclinical Studies
The effects of bitter compounds on GLP-1 secretion have been studied
extensively [1,3,50,51,78–81,83–87]. A number of bitter compounds have been shown to
stimulate GLP-1 in both cell line and animal studies. For example, berberine, found in
several bitter plants, stimulated GLP-1 in human enteroendocrine NCI-H716 cells, and
phenylthiourea in HuTu-80 cells around 1.5- to 2-fold, by activating TAS2R38 [50,80,81].
The latter effect was diminished, but not abolished, by silencing the TAS2R38 using
non-coding small interfering RNA [50], indicating that while this receptor is involved
in phenylthiourea-induced GLP-1 release, other mechanisms also contribute. In NCI-H716
cells, 1,10-phenanthroline stimulated GLP-1 via activation of TAS2R5, and denatonium
benzoate via a range of TAS2R subtypes, including TAS2R4, 43, and 46 [3,51]. In mouse
SCT-1 cells, application of the bitter compounds, MHBA and KDT501, pure derivatives of
isohumulone, extracted from hops, stimulated GLP-1 release 1.5- to 2.5-fold [78,84], and
the effect of KDT501 was attenuated by silencing the TAS2R108 with small hairpin RNA,
implicating a role for this receptor [84]. Moreover, 1,10-phenanthroline, as well as the
selective TAS2R14 agonists, vanillic acid and flufenamic acid, stimulated GLP-1 release
from ileal segments from rat ~1.5-fold [79].
In mice, oral administration of 1 mg/kg denatonium benzoate and 5 g/kg wild bitter
gourd, prior to glucose gavage, or 200 mg/kg propylthiouracil, stimulated GLP-1 secretion
~2–3 fold in all studies [3,50,87]. These doses were equivalent to ~70 mg, ~350 g and
~14 g in a 70 kg person, and were, accordingly, high. In diet-induced obese mice, acute
oral gavage of KDT501, in the dose of 150 mg/kg, prior to an oral glucose load (1 g/kg),
stimulated GLP-1 levels 3-fold within 15 min, while chronic treatment (150 mg/kg daily) for
17 weeks resulted in a more than 10-fold increase in plasma GLP-1 within four days, with
the effect sustained over the treatment period [84]. Moreover, in obese mice, intragastric
administration of denatonium benzoate (60 µmol/kg), but not quinine hydrochloride
(160 µmol/kg), for four weeks also stimulated plasma GLP-1 ~1.5-fold [1].
3.2.2. Outcomes of Studies in Healthy Humans
AmarasateTM, in a dose of 500 mg, also stimulated GLP-1, however, no information
was provided about the magnitude of the effect [72]. Two studies that evaluated the effects
of quinine (given as quinine hydrochloride) provided evidence that the timing of adminis-
tration influenced the effect on GLP-1 [17,20]. In the first study, intragastric administration
of quinine, in doses of 275 mg and 600 mg, 30 min before a 350-mL mixed-nutrient drink
(500 kcal, 74 g carbohydrates) did not stimulate plasma GLP-1 during the first 30 min (i.e.,
in response to quinine alone), but increased GLP-1 modestly (by ~15 pmol/L) following the
drink [17]. In the second study [20], 600 mg quinine was administered either intragastrically
60 min before, or intraduodenally 30 min before, a nutrient drink, and in both conditions
plasma GLP-1 was increased modestly, by quinine alone, and further following the drink
(Figure 1). These observations suggest that intragastric administration may require a longer
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time to achieve a comparable effect to that of intraduodenal administration, implying that
exposure of small intestinal bitter receptors to quinine may be necessary for stimulation of
GLP-1. In contrast to these observations, continuous intraduodenal infusion of quinine,
in a dose of 75 mg, over 60 min had no effect on GLP-1 [74], perhaps because a threshold
concentration was not achieved at the location of the receptors. The 600-mg dose of quinine
hydrochloride in the above studies [17,20] is comparable to the acute therapeutic dose of
quinine (500 mg) used for malaria treatment.




Figure 1. Effects of quinine on (A) plasma glucagon-like peptide-1 (GLP-1), (B) plasma C-peptide, 
(C) gastric emptying (measured using a 13C-acetate breath test) and (D) plasma glucose in 14 healthy 
men. Quinine, given as quinine hydrochloride in a dose of 600 mg, or control, was administered 
either intragastrically (IG, at t = −61 min), or intraduodenally (ID, at t = −31 min), before a mixed-
nutrient drink (500 kcal, 74 g carbohydrates), consumed at t = −1 min. IG and ID administration of 
quinine comparably (A) increased plasma GLP-1 concentration before, and in response to, the drink, 
(B) increased plasma C-peptide, before, and during the first 10 min in response to, the drink, (C) 
slowed gastric emptying of the drink, and (D) reduced plasma glucose before, and particularly follow-
ing, the drink (Reprinted with permission from ref. [20]. Copyright 2021 Oxford University Press). 
3.4. Ghrelin 
3.4.1. Outcomes of Preclinical Studies 
The effects of bitter compounds on ghrelin secretion have been investigated in a num-
ber of studies in both cell and rodent models; the majority of these have been performed 
by one research group [1,14,52,82]. Denatonium benzoate (0.5, 1 and 5 mmol/L), chloro-
quine (0.5, 1 and 5 mmol/L), 1,10-phenanthroline (0.1, 1 mmol/L), a selective agonist for 
TAS2R5, and erythromycin A (0.03, 0.3, 1 mmol/l), a TAS2R10-specific agonist, all stimu-
late ghrelin secretion in cultures of human fundic mucosa ~2-fold [52]. In a study, which 
evaluated the effects of phenolic extracts from grape seed, effects varied substantially be-
tween compounds, depending on the study conditions [82]. For example, epicatechin gal-
late, an agonist of mTAS2R14 and mTAS2R39, inhibited ghrelin secretion in a mouse gas-
tric ghrelinoma cell line, MGN3-1, at the low dose of 10 µM by ~20%, while stimulating 
ghrelin 2-fold at a high dose (500 µM) [82]. Gallic acid also inhibited ghrelin release from 
MGN3-1 cells by ~20% (although only a 10 µM dose was tested), and by ~33% in rats pre-
treated with gallic acid for 8 days [82]. In wild-type mice, intragastric administration of a 
mixture of bitter compounds containing denatonium benzoate, quinine hydrochloride, 
phenylthiocarbamide, propylthiouracil and D-salicin, stimulated plasma ghrelin ~2-fold 
[14]. In contrast, in obese mice on a high-fat diet, daily gavage with quinine (160 µmol/kg) 
had no effect on plasma ghrelin [1]. Thus, a range of bitter compounds stimulate ghrelin 
secretion in-vitro, while the outcomes of animal studies are inconsistent. 
  
Figure 1. Effects of quinine on (A) plasma glucagon-like peptide-1 (GLP-1), (B) plasma C-peptide, (C) gastric emptying
(measured using a 13C-acetate breath test) and (D) plasma glucose in 14 healthy men. Quinine, given as quinine hy-
drochloride in a dose of 600 mg, or control, was administe e e ther intragastrically (IG, at t = −61 min), or in raduodenally
(ID, at t = −31 min), before a mixed-nutrient drink (500 kcal, 74 g carbohydrates), consu ed at t = −1 in. IG and ID
administration of quinine comparably (A) increased plasma GLP-1 concentration before, and in response to, the drink, (B)
increased plasma C-peptide, before, and during the first 10 min in response to, the drink, (C) slowed gastric emptying of the
drink, and (D) reduced plasma glucose before, and particularly following, the drink (Adapted from ref. [20]).
3.3. Peptide YY
3.3.1. Outcomes of Preclinical Studies
Information relating to the effects of bitter compounds on PYY secretion is both
limited and inconsistent [3,78,79]. While, in murine NCI-H716 cells, denatonium benzoate
(2 mmol/L) stimulated PYY release ~2.3 fold [3], in murine STC-1 cells, administration
of MHBA was reported to have no effect [78]. Since PYY is co-localised with GLP-1 in
enteroendocrine L-cells [88], the effects of bitter substances on PYY would be expected
to be comparable to those on GLP-1. It is, accordingly, surprising that this has not been
investigated, particularly, given the important role of PYY in the regulation of energy
intake [54].
3.3.2. Outcomes of Studies in Healthy Humans
While amarasateTM was reported to stimulate plasma PYY [72], small intestinal ad-
ministration of 100 mg bitter secoiridoids [73] and a 60-min intraduodenal infusion of
quinine, in the dose of 75 mg [74], were found to be ineffective.
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3.4. Ghrelin
3.4.1. Outcomes of Preclinical Studies
The effects of bitter compounds on ghrelin secretion have been investigated in a num-
ber of studies in both cell and rodent models; the majority of these have been performed by
one research group [1,14,52,82]. Denatonium benzoate (0.5, 1 and 5 mmol/L), chloroquine
(0.5, 1 and 5 mmol/L), 1,10-phenanthroline (0.1, 1 mmol/L), a selective agonist for TAS2R5,
and erythromycin A (0.03, 0.3, 1 mmol/L), a TAS2R10-specific agonist, all stimulate ghrelin
secretion in cultures of human fundic mucosa ~2-fold [52]. In a study, which evaluated
the effects of phenolic extracts from grape seed, effects varied substantially between com-
pounds, depending on the study conditions [82]. For example, epicatechin gallate, an
agonist of mTAS2R14 and mTAS2R39, inhibited ghrelin secretion in a mouse gastric ghre-
linoma cell line, MGN3-1, at the low dose of 10 µM by ~20%, while stimulating ghrelin
2-fold at a high dose (500 µM) [82]. Gallic acid also inhibited ghrelin release from MGN3-1
cells by ~20% (although only a 10 µM dose was tested), and by ~33% in rats pre-treated
with gallic acid for 8 days [82]. In wild-type mice, intragastric administration of a mixture
of bitter compounds containing denatonium benzoate, quinine hydrochloride, phenylth-
iocarbamide, propylthiouracil and D-salicin, stimulated plasma ghrelin ~2-fold [14]. In
contrast, in obese mice on a high-fat diet, daily gavage with quinine (160 µmol/kg) had no
effect on plasma ghrelin [1]. Thus, a range of bitter compounds stimulate ghrelin secretion
in-vitro, while the outcomes of animal studies are inconsistent.
3.4.2. Outcomes of Studies in Healthy Humans
Intragastric administration of quinine, in a dose of 10 µmol/kg, suppressed plasma
ghrelin in males [18] and females [75] modestly, and intragastric administration of denato-
nium benzoate, in a dose of 1 µmol/kg in healthy females [19], or administration of 100 mg
bitter secoiridoids into the small intestine in healthy males and females [73], had no effect.
Thus, evidence for a ghrelin-suppressant effect of bitter substances is limited.
Taken together, there is persuasive evidence that bitter substances have the capacity
to stimulate gut hormones via a number of specific bitter receptor subtypes, and that
subtypes vary between compounds and hormones, however, much more work is required
to characterise their involvement. Identification of the specific role of specific receptor
subtypes will facilitate targeted use of bitter compounds for defined outcomes. The doses
used, particularly in the animal models have, in many cases, been very high, as assessed by
calculating equivalent doses in humans. Thus, whether such doses could be used safely in
humans, and/or whether lower doses have substantial effects, remains to be determined.
The possibility that, because of the high doses used, some of the observed effects may
reflect ‘non-specific’ effects of bitter compounds, requires clarification. For example, some
bitter agonists used in these studies (e.g., phenylthiocarbamide), at the doses administered,
have, in other studies, been shown to induce potent Ca2+ responses in control cells devoid
of bitter receptors [89]. It should also be appreciated that because no studies have included
positive controls, e.g., dietary nutrients, interpretation of the relative magnitude, and the
relevance, of the observed effects on hormone release is confounded. Finally, there is a lack
of information about the tolerability of bitter compounds, and the possibility that, at least
some of, the observed effects reflect an aversive response, requires investigation.
In contrast to preclinical studies, the effects of bitter substances on gut hormone
secretion in humans are largely inconclusive, moreover, the range of bitter compounds
studied is limited. While it appears that, in line with preclinical studies, certain bitter
compounds are associated with stimulation of GLP-1 in humans, the particular receptor
subtype(s) involved remain to be identified. For example, whether stimulation of TAS2R38,
which has been identified as a potent mediator of GLP-1 in in-vitro studies using human
tissue [50], plays a role or other receptor subtypes (e.g., TAS2R5 or 14) are involved, given
that quinine does not stimulate TAS2R38. Studies are required to systematically evaluate
the effects of specifically selected compounds (e.g., those activating only specific single
receptor subtypes) including targeting specific GI regions (e.g., the duodenum). Given that
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frequently much higher doses were used in preclinical studies, it will also be important to
determine whether pharmacological doses are, indeed, necessary to achieve substantial
effects and, if so, whether these occur in the absence of adverse effects.
4. Effects of Bitter Substances on Gastric Emptying and Gastrointestinal Motility
Gastric emptying regulates the transfer of chyme, and, therefore, the rate of nutri-
ent entry, to the small intestine. Slowing of gastric emptying reflects closely coordinated
changes in the motor function of the stomach and small intestine, which include relax-
ation of the proximal stomach, tonic and phasic pyloric contractions and suppression of
antral and duodenal pressures [90,91]. As gastric emptying progresses, food components,
particularly dietary nutrients, interact with specialised receptors located on the surface of
enteroendocrine cells, triggering the secretion of gut hormones [22,40,42–44,48], which, at
least in part, mediate nutrient-induced slowing of gastric emptying. The latter prolongs
gastric distension and, thereby, enhances the feeling of fullness after a meal [92,93]. While
both proximal and distal gastric filling contribute to the perception of fullness [93–95],
antral content has been shown to be related closely to energy intake [95], and is, therefore,
likely to be a major ‘intragastric’ mechanism.
Gastric emptying also plays a key role in the postprandial glycaemic response; in
this context, regulation of the small intestinal delivery, and subsequent absorption, of
glucose, as well as the release of glucoregulatory hormones, including GLP-1 and GIP, are
of particular relevance. Thus, gastric emptying accounts for ~35% of the variance in the
early (approximately first 30–45 min) rise in postprandial glucose in healthy individuals
and those with diabetes [96,97]. It is now also recognised that the primary action of GLP-1
to lower blood glucose probably occurs via slowing of gastric emptying [98,99].
4.1. Outcomes of Preclinical Studies
Preclinical studies suggest that bitter compounds slow gastric emptying and mod-
ulate gastric motility [14,15,100,101] (Table 3). For example, in normal-weight mice, in-
tragastric administration of phenylthiocarbamide (30 µmol/kg) or denatonium benzoate
(60 µmol/kg) slowed gastric emptying [15], while in another study intragastric administra-
tion of denatonium benzoate in the higher dose of 10 mM had no effect [14]. The reason(s)
for the discrepancy between the two studies are not clear. In the former study [15], the
effect of denatonium benzoate, but not phenylthiocarbamide, was abolished by probenecid
(50 mg/kg), an inhibitor of the TAS2R16, 38 and 43 subtypes, suggesting that the effect
of denatonium benzoate may be mediated via TAS2R43 (denatonium benzoate does not
activate TAS2R16 and 38), while raising the possibility that the effect of phenylthiocar-
bamide, which only activates TAS2R38, on gastric emptying does not involve bitter receptor
activation. The mixture of denatonium benzoate, quinine hydrochloride, phenylthiocar-
bamide, propylthiouracil and D-salicin, described above, also slowed gastric emptying,
which was unaffected by co-administration of the CCK antagonist, devazepide, or the
GLP-1 antagonist, exendin (9–39) [14], indicating that slowing of gastric emptying induced
by this mixture, and in the doses administered, was not mediated by CCK or GLP-1, but, as
evidenced by the inhibition of the electrical field stimulation-induced activity in both antral
and duodenal smooth-muscle strips, was likely to reflect a direct inhibitory effect on gastric
smooth muscle cells [14,15]. In contrast, in mice, oral administration of swertiamarin, an
extract from the Swertia japonica plant, in doses of 250 or 500 mg/kg, was reported to
accelerate gastric emptying [100].
A few studies have evaluated the effect of bitter compounds on gastric contractile
activity, and the reported effects vary substantially among the various compounds, as
well as across species. For example, in mouse fundic and antral smooth-muscle strips,
denatonium benzoate triggered concentration-dependent tonic fundic contraction (max-
imal at 100 µM) and antral phasic activity, but at higher concentrations (1 mM) induced
fundic relaxation and inhibited antral activity [15]. In contrast, phenylthiocarbamide only
induced dose-related relaxation of fundic muscle, while completely inhibiting activity
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in antral muscle, and salicin was ineffective [15]. These fundus-relaxing and antrum-
inhibitory effects would be consistent with the observed slowing of gastric emptying in
the in-vivo investigations [15]. In contrast to the effects observed in mouse tissue [15], in
guinea pigs, oral (0.2 nmol/mL) and intragastric (0.1 and 1 nmol/kg) administration of
denatonium benzoate increased gastric accommodation, consistent with gastric relaxation,
while the higher dose of 30 µmol/kg inhibited accommodation [101]. Finally, in mice, oral
administration of swertiamarin, in doses of 250 or 500 mg/kg, increased small intestinal
motility [100]. The observed differences between some of the bitter compounds (and be-
tween species) are likely to be attributable to a number of factors, including the differential
involvement of specific bitter taste receptor subtypes and variations in the sensitivity to
different compounds.
There is, accordingly, evidence that bitter substances slow gastric emptying and
modulate aspects of GI motility, although how some of the observed effects on motility
(e.g., increased fundic tone) can be reconciled with the slowing of gastric emptying observed
in vivo remains to be determined.
Table 3. Effects of bitter substances on gastric emptying and gastric motor function in preclinical models.
Bitter Tastants Model Doses Given/Locationof Delivery
Approx. Equivalent Dose in
a 70-kg Human 1
Observed Effect Ref #







↑ Phasic antral activity
↔ Tonic fundic contraction
↓ Phasic antral activity
↑ Fundic relaxation
[15]







↑ Tonic fundic contraction and
phasic antral activity
↑ Fundic relaxation
↓ Phasic antral activity
[15]
Mice 60 µmol/kg/IG ≈1.8 g ↓ Gastric emptying
↓ Fundic and antral motility
[15]
Mice 10 mM/IG ≈0.04 g ↔ Gastric emptying [14]
Rats 10 mM/IG ≈0.04 g ↓ Gastric emptying [102]









Phenylthiocarbamide Mouse fundic and
antral smooth-muscle
strips
10 µM–10 mM − ↑ Fundic relaxation
↓ Antral activity
[15]
Mice 30 µmol/kg/IG ≈3.2 g ↓ Gastric emptying
↓ Fundic and antral motility
[15]
Salicin Mouse fundic and
antral smooth-muscle
strips
10 µM–10 mM − ↔ Fundic and antral contractility [15]
Swertiamarin Mice 250, 500 mg/kg/oral ≈17.5 and 35 g ↑ Gastric emptying
↑ Small intestinal motility
[100]
Mixture of DB, PTC,
PTU, quinine HCl,
D-salicin





DB ≈ 46 mg;
PTC ≈ 15 mg;
PTU ≈8 mg; quinine ≈ 5 mg;
D-salicin ≈ 15 mg
↓ Gastric emptying [14]
DB, denatonium benzoate; HCl, hydrochloride; IG, intragastric; PTC, phenylthiocarbamide; PTU, propylthiouracil. 1 Only calculated for
whole-animal studies.
4.2. Outcomes of Studies in Healthy Humans
A number of studies have evaluated the effect of bitter compounds on gastric empty-
ing [16,17,19,20,103,104], with the majority reporting no effects [16,17,19,103] (Table 4). For
example, in healthy males and females, 18 mg quinine hydrochloride, ingested orally in an
acid-resistant capsule (to target release in the duodenum) did not affect gastric emptying
of a 480-kcal solid meal [16]. Moreover, in healthy females, intragastric administration
of 1 µmol/kg denatonium benzoate had no effect on gastric emptying of a 500-kcal pan-
cake [19]. Finally, in healthy males, intragastric administration of quinine hydrochloride,
in doses of 275 and 600 mg, had no effect on gastric emptying of a mixed-nutrient drink
(350 mL; 500 kcal) consumed 30 min later [17]. In contrast, when the higher dose of quinine
(600 mg) was administered either intragastrically 60 min, or intraduodenally 30 min, before
the nutrient-drink, gastric emptying was slowed, with no difference between the two
routes of administration (Figure 1) [20], providing evidence that intestinal exposure to
bitter substances may be critical.
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Table 4. Effects of bitter substances on gastric emptying and gastroduodenal motor function in healthy humans.
Bitter Tastants Model Doses Given/Location of Delivery Observed Effect Ref #
Denatonium benzoate Females 1 µmol/kg bolus/IG (≈30 mg) 1 ↔ Gastric emptying [19]
Males and females 1 µmol/kg bolus/IG ↓ Fundic relaxation [15]
Naringin Males and females 1 mM bolus (≈580 mg)/IG ↔ Gastric emptying [103]
Quinine hydrochloride Males and females 18 mg in acid-resistant capsule/oral ↔ Gastric emptying [16]
Females 10 µmol/kg bolus/IG [≈270 mg] ↓ ‘Fluctuations’ in antral motility
↔ Duodenal motility
[75]
Males and females 0.198 mM [≈72 mg]/IG ↔ Gastric emptying [103]
Males 37.5, 75, 225 mg/ID over 60 min ↔ Antropyloroduodenal motility [76]
Males 275, 600 mg bolus/IG 30 min before meal ↔ Gastric emptying [17]
Males 600 mg bolus/IG 60 min before meal, ID
30 min before meal
↓ Gastric emptying [20]
Quinine sulphate Females 10 mg bolus/oral ↓ Gastric emptying [104]
ID, intraduodenal; IG, intragastric. 1 Approximately equivalent dose in a 70-kg human.
Information relating to the effect of bitter substances on gastroduodenal motility is
also limited and inconsistent. In healthy males and females, intragastric administration
of denatonium benzoate attenuated fundic relaxation after a nutrient drink [15], while,
in healthy females, intragastric administration of quinine hydrochloride was reported to
reduce ‘fluctuations’ in fasting antral motility, without affecting duodenal motility [75],
and, in healthy males, a 60-min intraduodenal infusion of quinine, delivering overall doses
of 37.5 mg, 75 mg or 225 mg, did not affect antral, pyloric or duodenal pressures [76].
Thus, while animal studies demonstrate an effect of bitter substances to slow gastric
emptying, the effects on gastric emptying in humans, as well as any contributing contractile
mechanisms, remain uncertain. Both the timing and location of delivery may be important.
5. Effects of Bitter Substances on Energy Intake
Based on the findings in preclinical studies of potent modulation by bitter substances
of key GI factors, i.e., gut hormones and gastric emptying, involved in the acute regulation
of food intake, there has been considerable interest in evaluating the effects of bitter
substances on eating. This section will discuss studies that have investigated effects on
caloric intake.
5.1. Outcomes of Preclinical Studies
A number of preclinical studies have evaluated the effects of bitter compounds on
food intake [1,14,79,105–109] (Table 5). For example, in rats, oral gavage of an extract
from Hoodia gordonii (in doses of 6.25–50 mg/kg) for three days suppressed intake from
an ad libitum standard laboratory diet for eight days post-administration, and reduced
body weight [107]. In rats with impaired glucose tolerance, oral administration of berberin
(doses: 93.75, 187.5 or 562.5 mg/kg) for eight weeks reduced food intake from an ad
libitum high-fat laboratory chow and also attenuated weight gain [108]. Moreover, in
rats, ad-libitum consumption of a powdered chow diet containing quinine sulphate (0.75%
by weight) for 32 days was associated with a reduction in food intake and body weight
during the first two days of treatment, although food intake returned to control levels
within 2 weeks [109]. While these observations suggest that these bitter compounds have
an intake-suppressant effect, the bitter taste associated with oral consumption may have
been offensive and discouraged food intake. However, the fact that bitter substances
also reduce food intake when administered directly into the stomach argues against this
possibility. For example, in mice, acute intragastric administration of a mixture of bitter
compounds, including denatonium benzoate, quinine hydrochloride, phenylthiocarbamide,
propylthiouracil and D-salicin, while increasing food intake during the first 30 min post-
administration, suppressed intake during the subsequent 4 h [14]. The initial increase may
potentially reflect stimulation of ghrelin, while the subsequent inhibition was interpreted
as reflecting slowing of gastric emptying (despite continued elevation of ghrelin) [14].
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Table 5. Effects of bitter substances on food intake and body weight in preclinical models.
Bitter Tastants Model Doses Given/Location ofDelivery
Approx. Equivalent Dose
in a 70-kg Human Type of Meal or Diet Observed Effects Ref #
Berberine Rats 93.75, 187.5, 562.5
mg/kg/oral





Mice 60 µmol/kg/IG ≈1.8 g Mixed-nutrient liquid meal ↓ Food intake
↓Weight gain
[1]
Epicatechin Rats 300 mg/kg/IG ≈21 g Ad libitum standard chow diet ↓ Food intake [79]
Hoodia gordonii
extract
Rats 6.25–50 mg/kg/oral ≈0.4–3.5 g Ad libitum standard diet (55%






Mice 2–5% of diet/oral - Ad libitum standard (77% CHO,





Rodents 0.2–1.2% of diet/oral - Ad libitum standard diet (77%
CHO, 9.7% F, 13.9% Prot) or





1,10-Phenanthroline Rats 200 mg/kg/IG ≈14 g Ad libitum standard chow diet ↓ Food intake [79]
Quinine
hydrochloride
Mice 160 µmol/kg/IG ≈4 g Mixed-nutrient liquid meal ↔ Food intake
↓Weight gain
[1]
Quinine sulphate Rats 0.75% of diet/oral - Ad libitum powdered chow diet ↓ Food intake
↓ Body weight
[109]
Vanillic acid Rats 252 mg/kg/IG ≈17 g Ad libitum standard chow diet ↓ Food intake [79]
Mixture of DB, PTC,
PTU, quinine HCl,
D-salicin





DB ≈ 46 mg;
PTC ≈ 15 mg;
PTU, ≈8 mg;
quinine ≈ 5 mg;
Salicin ≈ 15 mg





CHO, carbohydrate; DB, denatonium benzoate; F, fat; HCl, hydrochloride; IG, intragastric; Prot, protein; PTC, phenylthiocarbamide;
PTU, propylthiouracil.
Moreover, in diet-induced obese mice, intragastric administration of 60 µmol/kg
denatonium benzoate for 4 weeks reduced food intake from a liquid meal [1], an effect
associated with GLP-1 stimulation. Interestingly, intragastric administration of quinine, in a
dose of 160 µmol/kg and using the same study protocol [1], failed to either stimulate GLP-1
or reduce food intake. Furthermore, despite apparent discrepant effects on food intake,
both denatonium benzoate and quinine reduced weight gain in mice [1], suggesting that
the effect of quinine on body weight may be mediated by other mechanisms. In support of
this concept, some bitter substances, including bitter orange extracts [110] and a mixture
of salicin and naringin [111], have been reported to increase resting energy expenditure
and diet-induced thermogenesis in the absence of a reduction in food intake, associated
with weight loss. Finally in rats, intragastric administration of agonists of hTAS2R5 (e.g.,
1,10-phenantroline in a dose of 200 mg/kg) and hTAS2R14 (e.g., vanillic acid in a dose of
252 mg/kg), but not hTAS2R39 agonists, reduced food intake from an ad-libitum standard
chow diet 3, 12 and 20 h post-administration [74]. The food intake-suppressant effect
of 1,10-phenantroline was associated with CCK and GLP-1 stimulation, and the effect of
vanillic acid with GLP-1 stimulation, as measured using excised intestinal tissue [74].
5.2. Outcomes of Studies in Healthy Humans
There is little information about the effects of bitter compounds on appetite or energy
intake in humans, and the reported outcomes are inconclusive [16–19,72–74,76] (Table 6).
For example, in healthy females, while intragastric administration of denatonium benzoate
(1 µmol/kg) increased ‘satiety’ and reduced hunger after a standardised meal, there was
no significant suppression of energy intake from a subsequent ad-libitum buffet meal [19].
In contrast, in healthy males and females, ingestion of 18 mg quinine hydrochloride in an
acid-resistant capsule modestly reduced energy intake from an ad-libitum meal 60 min later
by ~82 kcal [16], and an intragastric bolus of 10 µmol/kg (~250 mg) quinine hydrochloride,
in healthy females, modestly reduced energy intake from a highly palatable chocolate
milk shake, by ~67 kcal [18]. The latter effect was associated with ghrelin suppression
and an increased activity of brain centres involved in the control of feeding, including the
hypothalamus and hedonic regions [18]. On the other hand, intraduodenal infusion of
75 mg quinine hydrochloride, in healthy volunteers (6 men, 9 women) [74], or doses of
37.5, 75 and 225 mg over 60 min [76], or intragastric bolus administration, in doses 275
and 600 mg [17], in healthy males, did not affect energy intake from ad libitum meals.
Only two studies have reported more substantial reductions in energy intake. In one
study, including healthy males and females, consumption of a microencapsulated extract
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of bitter compounds, derived from Gentiana lutea root, incorporated in a standardised
custard breakfast (314 kcal), decreased total energy intake on that day by a substantial 22%
(~340 kcal) [73]. In the second study in healthy males, administration of amarasateTM, in a
dose of 500 mg, reduced energy intake from an ad-libitum lunch by 277 kcal, and from a
snack, provided 2 h after lunch, by 225 kcal [72].
Taken together, preclinical studies indicate consistent effects of bitter substances to
suppress food intake, associated with a reduction in body weight. In contrast, information
about the effects of bitter substances on energy intake in healthy humans remains limited,
and findings are inconsistent, although there is evidence that some bitter compounds
appear to have a potent suppressive effect.
Table 6. Effects of bitter substances on energy intake in healthy humans.
Bitter Tastants Model Doses Given/Location of Delivery Type of Meal or Diet Observed Effects Ref #
AmarasateTM 1 Males 500 mg in acid-resistant or standard
capsules/oral
Ad libitum lunch and snack ↓ Energy intake [72]
Denatonium benzoate Females 1 µmol/kg bolus/IG (≈30 mg) 2 Ad libitum meal (2330 kcal, 291
g CHO, 94 g F, 55 g Prot)
Trend for ↓ energy
intake
[19]
Quinine hydrochloride Males and
Females
18 mg in acid-resistant capsule/oral Ad-libitum meal (50% CHO,
31% F, 19% Prot)
↓ Energy intake [16]
Males and
Females
75 mg/ID over 60 min Ad libitum meal (160 kcal/100
g; 7.1 g Prot, 11 g CHO, 9.4 g F)
↔ Energy intake [74]
Females 10 µmol/kg bolus/IG (≈250 mg) Ad libitum palatable chocolate
milkshake
↓ Energy intake [18]
Males 37.5, 75, 225 mg/ID over 60 min Ad libitum meal (2300 kcal,
52% CHO, 27% F, 21% Prot)
↔ Energy intake [76]
Males 275, 600 mg bolus/IG 30 min before meal Ad libitum meal (2300 kcal,
52% CHO, 27% F, 21% Prot)
↔ Energy intake [17]




Ad libitum meal (3 h later) ↔ Energy intake [73]
CHO, carbohydrate; F, fat; ID, intraduodenal; IG, intragastric; Prot, protein. 1 Supercritical CO2 extract of New Zealand native hops plant,
2 approx. equivalent dose in a 70-kg human, 3 bitter compound derived from the Gentiana lutea plant.
6. Effects of Bitter Substances on Postprandial Blood Glucose
The potent effects of bitter substances to stimulate glucoregulatory hormones, par-
ticularly GLP-1, and slow gastric emptying (a major determinant of postprandial blood
glucose), have provided a rationale for the investigation of the capacity of these compounds
to reduce postprandial blood glucose levels. The latter is of major clinical relevance, since
it is now appreciated that in type 2 diabetes postprandial glycaemic excursions are the
major, and in many cases dominant, determinant of average glycaemic control, as assessed
by measurement of glycated haemoglobin (HbA1c).
6.1. Outcomes of Preclinical Studies
A consistent effect of bitter compounds to lower postprandial blood glucose has
been reported [3,83,87,110] (Table 7). For example, in db/db mice, oral administration of
denatonium benzoate, in a dose of 1 mg/kg, reduced blood glucose levels by ~2 mg/dL,
20–40 min after glucose gavage (5 g/kg) [3]. Similarly, in db/db mice, oral administration
of an extract from the root of the Gentia scabra plant immediately before an oral glucose
load (5 g/kg), reduced blood glucose—the dose of 100 mg/kg by ~1 mg/dL within 90 min,
and the 300 mg/kg dose by ~2 mg/dL within 40 min [83]. Moreover, in mice, a high-fat
diet containing 5% extract of bitter gourd for 5 weeks reduced blood glucose AUC during a
90-min oral glucose tolerance test (2 g/kg) by ~350 mg/dL·min [87]. The glucose-lowering
effects of denatonium benzoate, and Gentia scabra root and bitter gourd extracts, were
associated with stimulation of GLP-1 and insulin [3,83,87]. Moreover, the glucose-lowering
effect of bitter gourd extract was attenuated by co-administration of the GLP-1 receptor
antagonist, exendin (9–39)amide [87], supporting a role for GLP-1 in glucose-lowering.
The effect of bitter compounds to improve glycaemia may also relate to effects on
insulin sensitivity [110]. For example, in diabetic KK-Ay mice, the substantial postprandial
glucose-lowering effect of a diet containing 0.18% of either isohumulone or isocohumulone
(two major bitter acids derived from hops), fed for 14 days, was associated with activation of
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peroxisome proliferator activated receptors, PPARα and PPRAγ, intranuclear transcription
factors known to improve insulin resistance [110]. Moreover, in C57BL/6N high-fat diet-fed
mice, administration of isocohumulone (in doses of 10 and 100 mg/kg) for 14 days, reduced
the plasma glucose response to an oral glucose load (1 g/kg body weight), associated with
an improvement in insulin sensitivity [110].
Table 7. Effects of bitter substances on postprandial blood/plasma glucose in preclinical models and healthy humans.
Bitter Tastants Model Doses Given/Location of Delivery
Approx. Equivalent
Dose in a 70-kg
Human
Type of Meal ObservedEffects Ref #
(A) Preclinical models
Denatonium benzoate Mice 1 mg/kg/oral ≈70 mg OGTT (5 g glucose/kg BW) ↓ Blood
glucose
[3]
Gentiana scabra extract Mice 100, 300 mg/kg/oral ≈7–21 g OGTT (5 g glucose/kg BW) ↓ Blood
glucose
[83]
Isocohumulone 1 Mice 10, 100 mg/kg/oral ≈0.7–7 g OGTT (1 g glucose/kg BW) ↓ Plasma
glucose
[110]
Wild bitter gourd Mice High-fat diet containing 5%
extract/oral








Males 275, 600 mg/IG 30 min before meal Mixed-nutrient drink




Males 600 mg/IG 60 min before meal, ID
30 min before meal
Mixed-nutrient drink













BW, body weight; CHO, carbohydrate; ID, intraduodenal; IG, intragastric; N/A, not applicable; OGTT, oral glucose tolerance test. 1 Bitter
acid derived from hops plant, 2 blood glucose was measured in the fasting state, 3 bitter compound derived from the Gentiana lutea plant.
Accordingly, a number of bitter substances have potent effects to lower postprandial
blood glucose, although evidence to support the involvement of specific receptor subtypes
or the role of hormones, particularly GLP-1, is limited. No studies have hitherto evaluated
the relationship between the effects on blood glucose with slowing of gastric emptying.
6.2. Outcomes of Studies in Healthy Humans
The effects of bitter substances on postprandial blood glucose have been evaluated in
three studies in humans [17,20,73] (Table 7). Intragastric administration of quinine, in doses
of 275 and 600 mg, reduced the glucose response to a mixed-nutrient drink containing 74 g
carbohydrate in healthy males, associated with enhanced stimulation of GLP-1 and insulin
after the drink, but without any effect on gastric emptying [17]. In a subsequent study,
600 mg quinine given either intragastrically 60 min, or intraduodenally 30 min, before a
nutrient-drink also reduced blood glucose substantially, with no difference between the
two routes of administration (Figure 1) [20]. Moreover, quinine stimulated both plasma
GLP-1 and C-peptide (a measure of insulin secretion) immediately before the meal, and
also slowed gastric emptying. In this study, the early postprandial plasma glucose response
was shown to be related directly to gastric emptying, and inversely to plasma C-peptide
immediately before the drink [20], suggesting that both slowing of gastric emptying, as
well as insulin stimulation, contributed to glucose lowering. The role of GLP-1 in the
observed glucose-lowering is uncertain, given that GLP-1-induced insulin secretion is
glucose-dependent requiring plasma concentrations to be elevated above ~7 mmol/L [111].
Thus, it is possible that the glucose-lowering effect of quinine reflects a direct action of
quinine on pancreatic beta cells to stimulate insulin [112]. In contrast, the lack of effect of a
60-min intraduodenal in-fusion of quinine, delivering overall doses of 37.5, 75 and 225 mg,
in the absence of a carbohydrate source [76], is not surprising. Finally, in healthy males
and females, consumption of 100 mg microencapsulated of Gentiana lutea plant extract in a
custard and biscuit breakfast did not affect blood glucose over the subsequent 180 min [73].
However, only one dose was studied.
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Taken together, the available studies, although limited, suggest a substantial effect of
quinine, when administered into the upper GI lumen, to lower postprandial blood glucose.
7. Is There Evidence That Bitter Substances Reduce Body Weight and Improve Blood
Glucose Control in Obesity and Type 2 Diabetes?
While observations from preclinical studies have provided evidence for potent effects
of bitter substances to reduce food intake and lower postprandial blood glucose, in part
related to gut hormone secretion, leading to weight loss, observations in healthy humans
are less clear-cut, and, for the main part, effects, if any, were modest. Despite the latter,
conclusions are frequently drawn as to the major implications of these findings for the
development of novel management strategies for obesity and type 2 diabetes. We now
address whether this concept is supported adequately by studies in people with obesity
and/or type 2 diabetes.
A number of studies have reported associations between oral bitterness perception and
body mass index (BMI) [113–117]. For example, higher body weights have been reported
to be associated with reduced bitter perception in both adults (i.e., BMI > 28 kg/m2 vs.
BMI < 28 kg/m2) [116] and children and adolescents (i.e., body weight > 97th percentile vs.
body weight < 90th percentile) [117]. While impaired perception of sweet taste has been
reported in people with type 2 diabetes [118,119], findings relating to bitter taste perception
are less consistent. Some [119,120], but not all [121], studies have reported reduced oral
bitter perception in type 2 diabetes. For example, only ~57% of males and females with
well-controlled type 2 diabetes, compared with 72% of healthy individuals, were able to
identify a bitter stimulus correctly in a taste identification task, independent of gender,
disease duration or chronic glycaemic control, in one study [120], while another study
found no difference [121], although perception of other tastes, including sweet, sour and
salty was reduced.
GI morphological alterations, e.g., reduced numbers of enteroendocrine cells, both
in the stomach and duodenum, have been reported in morbidly obese, compared with
lean, people [122], which may potentially affect bitter sensing in the GI lumen, with
consequences for gut hormone release, food intake and/or blood glucose control. There is
evidence that the GI expression of some bitter taste receptor subtypes may be altered in
obesity [52,123]. For example, expression of TAS2R38 has been reported to be augmented
in colonic enteroendocrine cells producing CCK, GLP-1 and PYY in overweight and obese
people [123], although the effect on hormone release by bitter substances was not evaluated.
Moreover, in cultures of human gut mucosa, expression of TAS2R10 in ghrelin cells, which
was found in both gastric and jejunal tissue, was greater in obese individuals in the stomach,
but not the jejunum [52]. This was associated with differential effects on ghrelin stimulation
by denatonium benzoate; thus, while denatonium benzoate stimulated ghrelin release from
the fundus in both lean and obese, the effect was reduced in the obese, and in the jejunum,
ghrelin stimulation only occurred in lean individuals [52], suggesting that sensitivity of
ghrelin-secretory cells to this bitter agonist may be altered.
There is limited information regarding the effects of bitter sensing on glucose home-
ostasis [85,124]. While associations have been found between genetic variants of subtypes,
including TAS2R9 and TAS2R38, with the glucose response to an oral glucose tolerance
test [124] or GLP-1 and insulin release [85], the effects of bitter substances on blood glucose
control have, to date, not been investigated in clinical studies.
No studies have investigated the effects of bitter substances on gut hormone release
and gastric emptying in obesity and type 2 diabetes, and whether such effects, if any, are
associated with a reduction in energy intake, weight loss and long-term improvement in
blood glucose control.
8. Summary and Future Directions
In preclinical models bitter substances unequivocally have potent effects on upper GI
functions, particularly the secretion of gut hormones, including CCK, GLP-1 and ghrelin,
associated with reductions in food intake and body weight, and a reduction in postprandial
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blood glucose excursions, including in models of obesity and type 2 diabetes. In contrast,
the limited clinical studies have yielded much more inconsistent outcomes and only been
performed in healthy humans. These studies are indicative of an effect of bitter compounds
to stimulate GLP-1 and to lower postprandial glucose, and to reduce energy intake modestly
(Figure 2).
Nutrients 2021, 13, x FOR PEER REVIEW 18 of 24 
 
 
and in the jejunum, ghrelin stimulation only occurred in lean individuals [52], suggesting 
that sensitivity of ghrelin-secretory cells to this bitter agonist may be altered. 
There is limited information regarding the effects of bitter sensing on glucose home-
ostasis [85,124]. While associations have been found between genetic variants of subtypes, 
including TAS2R9 and TAS2R38, with the glucose response to an oral glucose tolerance 
test [124] or GLP-1 and insulin release [85], the effects of bitter substances on blood glucose 
control have, to date, not been investigated in clinical studies. 
No studies have investigated the effects of bitter substances on gut hormone release 
and gastric emptying in obesity and type 2 diabetes, and whether such effects, if any, are 
associated with a reduction in energy intake, weight loss and long-term improvement in 
blood glucose control. 
8. Summary and Future Directions 
In preclinical models bitter substances unequivocally have potent effects on upper 
GI functions, particularly the secretion of gut hormones, including CCK, GLP-1 and 
ghrelin, associated with reductions in food intake and body weight, and a reduction in 
postprandial blood glucose excursions, including in models of obesity and type 2 diabetes. 
In contrast, the limited clinical studies have yielded much more inconsistent outcomes 
and only been performed in healthy hu ans. These studies are indicative of an effect of 
bitter compounds to sti ulate GLP-1 and to lower postprandial glucose, and to reduce 
energy intake modestly (Figure 2). 
 
Figure 2. Schematic summarising current knowledge of effects of bitter substances on the secretion of gut hormones, in-
cluding cho-lecystokinin (CCK), glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and ghrelin, gastric emptying, energy 
intake and blood glucose, based on the outcomes of both preclinical studies (cell and animal models) and studies in healthy 
humans. TAS2R, bitter taste receptor. 
There are a number of important issues that need to be addressed. The range of avail-
able bitter substances, activating a large variety of combinations of bitter receptor sub-
types, not all of which may be relevant to outcomes, represents a major challenge to the 
systematic evaluation and comprehensive understanding of their effects. At least some of 
the inconsistencies in findings between humans and preclinical studies may be because 
the latter have often applied high doses of bitter compounds. Thus, evaluation of a wide 
Figure 2. Schematic summarising current knowledge of effects of bitter substances on the secretion of gut hormones,
including cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and ghrelin, gastric e t i , e r
t r l i t i lt
s. , itter t ste rece t r.
r are a number of important issues hat need to be addressed. The range of
vailabl bitter substan es, activating a large variety of combi ations of bitter receptor
subtypes, not all of w ich may b relevant t outcomes, represents a major challenge t t
s st tic l ti c r si rst i f t ir ff cts. t l st s f
t e i c siste cies i fi i s et ee a s a recli ical st ies a e eca se
the latter have often a lie high oses of bitter co o n s. h s, eval ation of a i e
range of bitter compounds, including a broad range of doses is required to determine
efficacy, as well as tolerability. Moreover, no studies have directly compared the effects of
different bitter compounds, administered intestinally, when adjusted for their bitterness,
i.e., at identical intensities, to assess their effects independent of bitterness intensity. There
is evidence that rats cannot discriminate orally between equibitter solutions of quinine
and denatonium benzoate [125]. Characterisation of the specific bitter receptor subtypes
involved in the regulation of GI functions, particularly the release of gut hormones, as
well as their regional distribution along the human GI tract, may be pivotal to targeted
use of specific bitter agonists to achieve defined outcomes, e.g., the release of specific gut
hormones and/or slowing of gastric emptying, as well as potency of these effects. The roles
of gut hormones and gastric emptying in the effects of bitter substances on energy intake
and blood glucose require additional investigation to define whether these are causal or
coincidental. Moreover, clarification of the role of genetic variations of receptor subtypes in
interindividual differences in bitterness perception, and their relationships with effects on
GI functions, energy intake and blood glucose control, is desirable.
A major omission is the absence of studies relating to the effects of bitter substances in
people with obesity and/or type 2 diabetes. Such studies, which would initially evaluate
acute effects, represent a priority. If the outcomes are positive, longer-term trials to establish
Nutrients 2021, 13, 1317 17 of 21
whether acute effects translate to sustained weight loss and long-term improvements in
glycaemic control will be warranted. Only then will it be known whether the encouraging
findings from laboratory-based studies can be translated into innovative strategies for the
management, treatment or prevention of obesity and type 2 diabetes.
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